臨床研究等提出・公開システム

A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist.(NN1535-4592) (COMBINE 2) (COMBINE 2)

A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2) (COMBINE 2)

Miwa Hirotaka

Novo Nordisk Pharma Ltd.

2-1-1, Marunouchi, Chiyodaku, Tokyo

JPHC_clinical_trials@novonordisk.com

Miwa Hirotaka

Novo Nordisk Pharma Ltd.

2-1-1, Marunouchi, Chiyodaku, Tokyo

+81-362661000

JPHC_clinical_trials@novonordisk.com

Complete

May. 27, 2022

Interventional

randomized controlled trial

open(masking not used)

active control

parallel assignment

treatment purpose

1. Male or female and age above or equal to 18 years at the time of signing informed consent.
2. Diagnosed with type 2 diabetes mellitus >=180 days before screening.
3. HbA1c of 7.0-10.0%(53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
4. Insulin naive. The following exceptions are permitted: short term insulin treatment for a maximum of 14 days before screening and/or prior insulin treatment for gestational diabetes.
5. Treated with stable doses of daily or weekly GLP-1 receptor agonist (excluding once weekly semaglutide with doses higher than 1.0 mg) according to local label for the treatment of diabetes >= 90 days before screening. The treatment can be with or without any of the following anti-diabetic drugs with stable doses >=90 days before screening
-Metformin
-Sulfonylureas
-Meglitinides (glinides)
-DPP-4 inhibitors
-Sodium-glucose co-transporter 2 inhibitors
-Alpha-glucosidase-inhibitors
-Thiazolidinediones
-Marketed oral combination products only including the products listed above.
6. Body mass index (BMI) <=40.0 kg/m2

1. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
2. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
3. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
4. Any episodesa of diabetic ketoacidosis within 90 days before screening.
5. Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
6. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening.
7. Chronic heart failure classified as being in New York Heart Association Class IV at screening.
8. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Both

type 2 diabetes

participants will be randomised (1:1) to receive once weekly IcoSema or once weekly semaglutide.

Change in HbA1c: From baseline week 0 (V2) to week 52 (V54)

Change in fasting plasma glucose (FPG):
From baseline week 0 (V2) to week 52 (V54)

Change in body weight:
From baseline week 0 (V2) to week 52 (V54)

Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3):
From baseline week 0 (V2) to week 57 (V56)

+81-92-283-7701

April. 14, 2022

No

Brazil/Canada/China/France/Greece/Hungary/Israel/Russia/Slovenia/Sweden/Switzerland/Taiwan,/United States